Dexfenfluramine: no increase in significant valvular abnormalities

    loading  Checking for direct PDF access through Ovid

Abstract

There appears to be no increase in the prevalence of clinically relevant mitral or aortic regurgitation following 2-3 months' therapy with the anorectic agent dexfenfluramine [‘Redux’], compared with placebo, according to the results of a study presented at the 47th Annual Scientific Sessions of the American College of Cardiology (ACC) [Atlanta, US; March 1998]. In addition, the prevalence of significant valvular regurgitation following treatment with dexfenfluramine appears to be much lower than previously reported.

Related Topics

    loading  Loading Related Articles